SCHEMBL16993298

SCHEMBL16993298

CCNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCOC3CCN(C(=O)OC(C)(C)C)CC3)c2n1

nearest known ligand 0.80

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 20/20 0.80
FGFR2 P21802 9/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16993370 0.93 FGFR1 (0.83) FGFR1FGFR2
SCHEMBL16993197 0.93 FGFR1 (0.80) FGFR1FGFR2
SCHEMBL16993250 0.89 FGFR1 (1.00) FGFR1FGFR2
SCHEMBL16993344 0.87 FGFR1 (0.62) FGFR1FGFR2
SCHEMBL16993021 0.87 FGFR1 (0.61) FGFR1FGFR2
SCHEMBL16993162 0.86 FGFR1 (0.79) FGFR1FGFR2
SCHEMBL16993352 0.86 FGFR1 (0.78) FGFR1FGFR2
SCHEMBL17910106 0.85 FGFR1 (0.79) FGFR1FGFR2
SCHEMBL16993426 0.85 FGFR1 (0.75) FGFR1FGFR2
SCHEMBL16993172 0.84 FGFR1 (0.78) FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMAC, INC. (US) 2024-12-10 US disclosed
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-03-21 US disclosed
US-20210292323-A1 Quinolone Derivatives as Fibroblast Growth Factor Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-09-23 US disclosed
US-11078199-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2021-08-03 US disclosed
US-20190233418-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2019-08-01 US disclosed
US-10294223-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2019-05-21 US disclosed
EP-3102577-B1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2018-07-18 EP disclosed
US-20180065960-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2018-03-08 US disclosed
US-9815834-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-11-14 US disclosed
US-9567334-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-02-14 US disclosed
EP-3102577-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS Principia Biopharma Inc. (US) 2016-12-14 EP disclosed
US-20160229849-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2016-08-11 US disclosed
US-20160200725-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2016-07-14 US disclosed
WO-2015120049-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA, INC. (US) 2015-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-11078199-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20160200725-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20210292323-A1 Quinolone Derivatives as Fibroblast Growth Factor Inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20190233418-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-10294223-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20160229849-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20180065960-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.